Collegium Pharmaceutical (NASDAQ: COLL) is a specialty pharmaceutical company that commercializes branded pain management medications. Revenue is generated through net product sales of its prescription drug portfolio to wholesalers, specialty distributors, and pharmacy benefit managers. The 10-K filed 2026-02-26 (accession 0001628280-26-011992) confirms Collegium operates as a commercial-stage specialty pharma business focused on pain and central nervous system conditions. The company's shares are listed on the Nasdaq Global Select Market with a par value of $0.001 per share.

Revenue model

Net product sales of branded prescription medications sold through pharmaceutical wholesalers, specialty distributors, and pharmacy channels.

Products and services

Branded prescription pain management and central nervous system medications. Specific product names are not confirmed by the available filing excerpts.

Customers and end markets

Wholesalers, specialty distributors, and pharmacy benefit managers serving the prescription pain management market. Specific customer concentration figures are not supported by the available excerpts.

Value-chain role

Commercial-stage specialty pharmaceutical company; brand owner and sales force operator downstream of drug manufacturing.

Geographic exposure

United States. Geographic mix beyond domestic operations is not supported by the available filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Amneal Pharmaceuticals Inc ANI Pharmaceuticals Inc BIODELIVERY SCIENCES INTERNATIONAL INC Edgewise Therapeutics Inc Nektar Therapeutics Johnson & Johnson Phibro Animal Health Corp Tricida, Inc.